APOE-TOMM40 in the Pharmacogenomics of Dementia

Journal of Pharmacogenomics & Pharmacoproteomics

doi 10.4172/2153-0645.1000135

Full Text

Abstract

Available in

Date

Authors

Publisher

OMICS Publishing Group

Related search

TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia

Journal of Alzheimer's Disease
GerontologyClinical PsychologyMental HealthPsychiatryGeriatricsMedicineNeuroscience
2012English

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2010English

The Influence of APOE and TOMM40 Polymorphisms on Hippocampal Volume and Episodic Memory in Old Age

Frontiers in Human Neuroscience
Mental HealthNeuropsychologyPhysiological PsychologyNeurologyBehavioral NeurosciencePsychiatryBiological Psychiatry
2013English

TOMM40 ′523 Variant and Cognitive Decline in Older Persons With APOE Ε3/3 Genotype

Neurology
Neurology
2017English

Alzheimer’s Disease Susceptibility Genes APOE and TOMM40, and Hippocampal Volumes in the Lothian Birth Cohort 1936

PLoS ONE
Multidisciplinary
2013English

TOMM40 Intron 6 Poly-T Length, Age at Onset, and Neuropathology of AD in Individuals With APOE Ɛ3/Ɛ3

Alzheimer's and Dementia
Molecular NeuroscienceGerontologyHealth PolicyDevelopmental NeuroscienceMental HealthEpidemiologyGeriatricsCellularPsychiatryNeurology
2012English

Prospective Belgian Study of Neurodegenerative and Vascular Dementia: APOE Genotype Effects

Journal of Medical Genetics
Genetics
2003English

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Clinical Pharmacology and Therapeutics
Pharmacology
2017English

PharmGKB: The Pharmacogenomics Knowledgebase

2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy